Press Releases

 
Press Releases
  Date Title and Summary View
Jan 8, 2018
AMES, Iowa, Jan. 08, 2018 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced Indigo301, the name of its upcoming Phase 3 trial of indoximod plus PD-1 inhibitors for patients with advanced melanoma, and outlined 2018 business priorities to support this trial. In addition, the company updated clinical and financial guida...
Dec 21, 2017
AMES, Iowa, Dec. 21, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) announced today that the company will present at the 36th Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2018, at 11:00am PT / 2:00pm ET in San Francisco, CA.  A live webcast of the conference presentation will be on the Company's webs...
Nov 27, 2017
AMES, Iowa, Nov. 27, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) will participate in the Global Mizuho Investor Conference on Tuesday, December 5th, in New York City.  The format of the conference is one-on-one meetings with investors only.  About NewLink Genetics Corporation NewLink Genetics is a late-stage biopharm...
Nov 20, 2017
AMES, Iowa, Nov. 20, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced the presentation of data from a Phase 1 study of indoximod, in combination with radiation, for children with progressive brain tumors.  These data were presented at the Society for NeuroOncology, 22nd Annual Meeting, in San Francisco, CA, on N...
Nov 14, 2017
AMES, Iowa, Nov. 14, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced the appointment of Eugene P. Kennedy, M.D., FACS, to the role of Chief Medical Officer. He will be responsible for leading all clinical development, medical affairs and related functions. Dr. Kennedy's previous role at NewLink Genetics was Vic...
Nov 13, 2017
AMES, Iowa, Nov. 13, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) will participate in the following investor conferences this week: Stifel 2017 Healthcare Conference on Tuesday, November 14th, at 5:00pm ET in New York CityJefferies 2017 London Healthcare Conference on Thursday, November 16th, at 17:20 GMT (12:20pm ET) ...
Nov 2, 2017
AMES, Iowa, Nov. 02, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today reported consolidated financial results for the third quarter of 2017 and provided updates on its clinical development program for indoximod, NewLink Genetics' IDO pathway inhibitor with a distinct mechanism of action. "We are pleased with the prog...
Oct 30, 2017
AMES, Iowa, Oct. 30, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that indoximod, its leading drug development candidate, was granted orphan-drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of patients with Stage IIb-IV melanoma.  "We are pleased to receive this orphan d...
Oct 20, 2017
AMES, Iowa, Oct. 20, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that it will release its third quarter 2017 financial results on Thursday, November 2, 2017. The company has scheduled a conference call for 8:30 AM ET the same day to discuss the results and to give an update on its clinical and development a...
Oct 3, 2017
AMES, Iowa, Oct. 03, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation ("NewLink Genetics") (Nasdaq:NLNK), a late-stage biopharmaceutical company, today announced the pricing of its underwritten public offering of 5,000,000 shares of its common stock at a price to the public of $10.25 per share.  All of the shares of common stock to be sold i...
Page:
1
... NextLast
= add release to Briefcase